Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590277 · ClinicalTrials.gov registry record · Phase 1
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans
A Phase 1 study of Alcohol Effect and Driving Under the Influence, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01590277 is a Phase 1 study of Alcohol Effect and Driving Under the Influence that has completed, run by VA Office of Research and Development. The registered enrollment target is 33 participants, below the 40-participant average among 4 other Alcohol Effect trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01590277, a Phase 1 study of Alcohol Effect and Driving Under the Influence, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Alcohol is abused commonly, but there is no remedy for alcohol intoxication. This project is looking at the substance iomazenil and its effect on alcohol intoxication and alcohol's effects on driving using a driving simulator.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Active Ethanol
- DRUG Active Iomazenil
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-12-14 |
| Est. Completion | 2018-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01590277
The ClinicalTrials.gov registry entry for NCT01590277 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 40-participant average among 4 other Alcohol Effect trials with a reported enrollment target (17% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Alcohol Effect appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01590277 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01590277 about?
NCT01590277 is a clinical study titled "Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans". Alcohol is abused commonly, but there is no remedy for alcohol intoxication. This project is looking at the substance iomazenil and its effect on alcohol intoxication and alcohol's effects on driving using a driving simulator.
What is the current status of trial NCT01590277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-12-14. Estimated completion is 2018-11-02.
What conditions does trial NCT01590277 study?
This clinical trial studies the following conditions: Alcohol Effect, Driving Under the Influence, Alcohol Impairment, Active Ethanol and Active Iomazenil, Active Ethanol and Placebo Iomazenil.
What interventions are being tested in trial NCT01590277?
The interventions under investigation include: Placebo (DRUG), Active Ethanol (DRUG), Active Iomazenil (DRUG).
Who is sponsoring clinical trial NCT01590277?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01590277 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Effect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
ACTIVE NOT RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
ACTIVE NOT RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
ACTIVE NOT RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.